Holen Sie sich die Stockscreener-App
2.295
5.94%
-0.145
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
A company developing cancer and rare-disease treatments will present at a conference Sept. 15. - Stock Titan
Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch - TipRanks
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Protara (TARA) Financial Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Market Reaction: The Stock Records a Flat Reaction in the Current UpdateForward EPS Estimate - vinanet.vn
Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics (TARA) Climbs 0.76% to $3.97 as Consolidation Builds Ahead of Clinical CatalystsBox Spread - dars.gov.et
Protara Therapeutics (TARA) Climbs 0.76% to $3.97 as Consolidation Builds Ahead of Clinical CatalystsCharm Flow - vinanet.vn
Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
Protara Therapeutics (TARA) Climbs 0.76% to $3.97 as Consolidation Builds Ahead of Clinical CatalystsPoint of Control - dars.gov.et
HC Wainwright Issues Negative Forecast for TARA Earnings - MarketBeat
Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA) - TradingView
Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA - MarketBeat
Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios - Stock Titan
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results - MarketBeat
Protara Therapeutics (TARA) Advances Clinical Trials Amid Mixed Market Signals - GuruFocus
Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7)M, EPS $(0.36) — 10-Q Summary - TradingView
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
Protara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com Canada
Protara Therapeutics reports Q2 2026 net loss $21.7M, cash ~$162M to fund operations into 2028 - TradingView
Protara Therapeutics: Q2 Earnings Snapshot - AOL.com
Protara Therapeutics: Q2 Earnings Snapshot - The Daily Gazette
Protara Therapeutics: Q2 Earnings Snapshot - 10TV
Press Release: Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - Moomoo
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - Yahoo Finance
Protara Therapeutics rated Buy with $9.96 fair value, advancing treatments for NMIBC and choline deficiency. - Pluang
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - GlobeNewswire
Protara Posts $21.7 Million Q2 Loss as Pipeline Milestones Near | TARA Stock News - Quiver Quantitative
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline - Seeking Alpha
Protara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key LevelsDark Pool Sentiment - dars.gov.et
Protara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key LevelsPercent Above MA - vinanet.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Protara Therapeutics (TARA) Projected to Announce Quarterly Earnings on Monday - MarketBeat
Protara Therapeutics Inc (TARA) Balance Sheet - TradingKey
Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TARA|Protara Therapeutics Inc|Price:3.975|Chg%:+0.055 - TradingKey
Protara Therapeutics Inc (TARA) Institutional Confidence - TradingKey
TARA|Protara Therapeutics Inc|Price:3.900|Chg%:-0.060 - TradingKey
TARA|Protara Therapeutics Inc|Price:4.030|Chg%:+0.010 - TradingKey
TradingKey - TradingKey
Walleye Capital LLC Boosts Position in Protara Therapeutics, Inc. $TARA - MarketBeat
What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
Protara Therapeutics (TARA) Edges Higher, Approaches Key Resistance Amid Low VolumeLong Term Entry Picks - vinanet.vn
Protara Therapeutics Q1 2026 Earnings: Narrower Loss Amid Continued Clinical DevelopmentHigh Growth Earnings - dars.gov.et
Protara Therapeutics (TARA) Edges Higher by 2.86%, Testing Resistance Near $4.54Equal Weight ETF - dars.gov.et
7.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):